Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when GHRP-2 crosses your target, drops, or sets a new tracked low—without daily noise.

Public product evidence22 certificate records mentioning this compound or product name4 provider-linked · 17 exact product matches

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

GH axis / secretagogue research

Primary research area: GH axis. Also surfaces under Performance for browsing and discovery.

Aliases

No major aliases are tracked for this profile yet.

Signal depth

Low

No FDA label signal · 0 trials · 204 PubMed results

Preclinical

Research evidence

Current evidence for GHRP-2 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

GHRP-2 has no clinical trials that name it and 204 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data

Lab / animal only

Trial quality

No human trials

Outcomes

No human trials

Replication

Multiple papers

Literature

High-impact

American Journal of Physiology-Endocrinology and Metabolism · 173 citationsAnti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats Peptides · 88 citationsEffects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH Journal of Endocrinology · 65 citationsThe Effect of GH-Releasing Peptide-2 (GHRP-2 or KP 102) on GH Secretion from Primary Cultured Ovine Pituitary Cells Can be Abolished by a Specific GH-Releasing Factor (GRF) Receptor Antagonist Journal ArticleThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Journal ArticlePossible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone.Case ReportsOne Case of Sudden Isolated Adrenocorticotropic Hormone (ACTH) Deficiency Diagnosed Based on Repeated Hypoglycemic Attacks.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What GHRP-2 is

GHRP-2 is one of the older growth hormone secretagogues that helped define the GH-focused peptide niche before the current metabolic-drug wave took over most attention.

Why it matters

It provides context for how the peptide market evolved. Many modern GH stacks and blends still reference earlier secretagogue-era compounds like GHRP-2.

Regulatory context

GHRP-2 is not an FDA-approved GH optimization treatment in the United States and should be read as a research-market profile.

Practical reading note

When comparing GH-related peptides, it helps to distinguish between branded medical therapies, diagnostic tools, and research-market secretagogues.